1. In Vivo

Why CAR T Therapies Are Hard To Scale, And How Challenges Can Be Solved

 
• By Eliza Slawther

Chimeric antigen receptor T-cell (CAR-T) therapies have revolutionized the treatment of blood cancer, but scalability remains a major challenge. Experts explain how technologies such as chip-based miniaturized models and automation could be part of the solution.  

3d illustration of immune system T cells attacking cancer cells (CAR T-cell therapy) - Illustration
• Source: Shutterstock

With complete remission success rates of up to 85% in blood cancer patients, chimeric antigen receptor T-cell (CAR-T) therapies have transformed cancer care since 2017, when Novartis AG’s Kymriah (tisagenlecleucel) became the first CAR-T to secure authorization from the US Food and Drug Administration.

There are now six CAR-T therapies authorized in the US, EU, and many other countries worldwide (see Exhibit 1). But...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Manufacturing Focus

More from In Vivo

Rising Leaders 2025: Doxie Jordan, From UNC Graduate To Global Market Strategist

 
• By Jo Shorthouse

Bristol Myers Squibb executive Doxie Jordan discusses his path to global commercial leadership and the principles guiding pharmaceutical market strategy

Podcast: Brain+ CEO Discusses “Groundbreaking” Potential Of CST Assistant For Dementia Patients

 
• By Anabel Costa-Ferreira

Devika Wood, CEO of Brain+, explains the importance of developing health tech solutions for dementia and the growing need to both raise awareness and improve overall access to nondrug interventions like CST.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By Jo Shorthouse

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.